Literature DB >> 10965615

Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokines and postoperative organ injury.

Y Sato1, S Ishikawa, A Otaki, T Takahashi, Y Hasegawa, M Suzuki, T Yamagishi, Y Morishita.   

Abstract

OBJECTIVE: A systemic inflammatory response after open-heart surgery using cardiopulmonary bypass may be responsible for postoperative organ dysfunction. Ulinastatin, a protease inhibitor, plays an important role in host defense under periods of stress.
METHODS: We studied the efficacy of ulinastatin on changes in acute-phase reactive substances during and after open-heart surgery. Patients undergoing open-heart surgery were divided into an ulinastatin group (Group U) and a control group (Group C). In Group U, we introduced 600,000 units of ulinastatin into a priming solution for cardiopulmonary bypass, 300,000 units into a cardiopulmonary bypass circuit at the removal of aortic cross-clamping, and 300,000 units a day for 5 days following surgery.
RESULTS: Immediately after cardiopulmonary bypass, alpha 1-antitrypsin levels decreased significantly in both groups, and increased significantly on the second day after surgery. Ulinastatin levels decreased after cardiopulmonary bypass in Group C. Significantly high levels of ulinastatin were obtained in Group U. Interleukin-6, interleukin-8, and polymorphonuclear elastase were markedly induced, and high levels of plasma concentration continued for several days after surgery. At all sample points, these concentrations in Group U tended to be lower than those in Group C. A significantly positive correlation was seen between the maximum levels of interleukin-8 and polymorphonuclear elastase, but these cytokine and polymorphonuclear elastase levels did not correlate with parameters such as the duration of anesthesia, surgery, cardiopulmonary bypass, or aortic cross-clamping.
CONCLUSIONS: Our study suggests that high-dose ulinastatin administration to maintain a sufficient concentration of circulating protease inhibitors may suppress overinduction of cytokines and polymorphonuclear elastase in open-heart surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965615     DOI: 10.1007/bf03218170

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  27 in total

1.  Humoral and cellular activation in a simulated extracorporeal circuit.

Authors:  N E Moat; N Rebuck; D F Shore; T W Evans; A H Finn
Journal:  Ann Thorac Surg       Date:  1993-12       Impact factor: 4.330

2.  [Effects of ulinastatin on changes of plasma granulocyte elastase, myeloperoxidase and fibronectin during and after open heart surgery].

Authors:  H Mitsuhata; K Enzan; J Hasegawa; S Matsumoto; M Yabe; J Matsumoto
Journal:  Masui       Date:  1990-09

Review 3.  Inflammatory response to cardiopulmonary bypass.

Authors:  J Butler; G M Rocker; S Westaby
Journal:  Ann Thorac Surg       Date:  1993-02       Impact factor: 4.330

4.  Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Effects on hemostasis, cytokines, and complement components.

Authors:  D Journois; P Pouard; W J Greeley; P Mauriat; P Vouhé; D Safran
Journal:  Anesthesiology       Date:  1994-11       Impact factor: 7.892

5.  The inhibitory actions of protease inhibitors on the production of polymorphonuclear leukocyte elastase and interleukin 8.

Authors:  S Endo; K Inada; H Yamashita; T Takakuwa; H Nakae; Y Yamada; T Kasai; K Taki; M Yoshida
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1993-10

6.  Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure.

Authors:  L C Casey
Journal:  Ann Thorac Surg       Date:  1993-11       Impact factor: 4.330

7.  [Usefulness of ulinastatin as a radical scavenger for protection of reperfusion injury after myocardial ischemia in open heart surgery].

Authors:  T Kawai; Y Wada; K Nishiyama; Y Kanki; K Ohga; T Oka; M Yasuda; T Yoshikawa
Journal:  Nihon Kyobu Geka Gakkai Zasshi       Date:  1991-12

8.  Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass.

Authors:  B Frering; I Philip; M Dehoux; C Rolland; J M Langlois; J M Desmonts
Journal:  J Thorac Cardiovasc Surg       Date:  1994-10       Impact factor: 5.209

9.  Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass.

Authors:  A B Millar; L Armstrong; J van der Linden; N Moat; R Ekroth; J Westwick; M Scallan; C Lincoln
Journal:  Ann Thorac Surg       Date:  1993-12       Impact factor: 4.330

10.  Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans.

Authors:  G E Hill; A Alonso; G M Thiele; R A Robbins
Journal:  Anesth Analg       Date:  1994-07       Impact factor: 5.108

View more
  7 in total

1.  Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery.

Authors:  Tomoki Nishiyama; Takeshi Yokoyama; Koichi Yamashita
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

2.  Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass.

Authors:  Se-Young Oh; Jong Chan Kim; Yong Seon Choi; Woo Kyung Lee; Yeong-Kyu Lee; Young Lan Kwak
Journal:  Korean J Anesthesiol       Date:  2012-02-20

3.  The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock.

Authors:  Kyung Hye Park; Kang Hyun Lee; Hyun Kim; Sung Oh Hwang
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

4.  Effects of ulinastatin on coagulation in high-risk patients undergoing off-pump coronary artery bypass graft surgery.

Authors:  Na-Young Kim; Jae-Kwang Shim; Seo-Ouk Bang; Jee-Suk Sim; Jong-Wook Song; Young-Lan Kwak
Journal:  Korean J Anesthesiol       Date:  2013-02-15

Review 5.  Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.

Authors:  Qiu-Lan He; Fei Zhong; Fang Ye; Ming Wei; Wei-Feng Liu; Mei-Na Li; Qiao-Bo Li; Wen-Qi Huang; Lai-Bao Sun; Hai-Hua Shu
Journal:  Biomed Res Int       Date:  2014-03-09       Impact factor: 3.411

6.  Effect of ulinastatin on post-operative blood loss and allogeneic transfusion in patients receiving cardiac surgery with cardiopulmonary bypass: a prospective randomized controlled study with 10-year follow-up.

Authors:  Peng Zhang; Hong Lv; Xia Qi; Wenjing Xiao; Qinghua Xue; Lei Zhang; Lihuan Li; Jia Shi
Journal:  J Cardiothorac Surg       Date:  2020-05-14       Impact factor: 1.637

7.  Evaluation of the pharmacological function of ulinastatin in experimental animals.

Authors:  Chong-En Xu; Meng-Yuan Zhang; Cheng-Wei Zou; Ling Guo
Journal:  Molecules       Date:  2012-07-31       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.